USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: ASURAGEN, INC.
Address: 2150 WOODWARD STREET
SUITE 100
AUSTIN, TX 78744-1840
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,144,706.00 4
SBIR Phase II $4,439,841.00 3

Award List:

Enabling use of blood spot cards for accurate high-throughput Fragile X screening

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gary J. Latham – 512-651-0200
Award Amount: $346,302.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop accurate, rapid, high-throughput and cost-effective diagnostic tests for Fragile X syndrome (FXS) and related disorders in anticipation of population screening needs. Newborn screening (NBS) for Fragile X is timely… More

Identification of microRNA Biomarkers for Colon Cancer Recurrence Risk Stratifica

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Elizabeth Mambo – 512-651-0200
Award Amount: $956,372.00
Abstract:
DESCRIPTION (provided by applicant): The current primary form of treatment for all stages of colon cancer is surgical resection, with overall survival rates depending upon whether the cancer recurs and metastasizes. The likelihood of recurrence is directlyrelated to the stage of cancer, which is… More

Technologies for Mapping Interspersed AGG Sequences in the FMR1 Gene

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Liangjing C. Chen – 512-651-0200
Award Amount: $1,329,604.00
Abstract:
DESCRIPTION (provided by applicant): The overall objective for this project is to validate, commercialize, and further establish the clinical utility of a comprehensive set of genotyping assays to improve screening and diagnosis of conditions associated with fragile X syndrome (FXS). The relevance… More

Integrated Bioinformatics Analysis Suite for deep, targeted amplicon sequencing

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ashish Choudhary – 512-681-5367
Award Amount: $242,940.00
Abstract:
DESCRIPTION (provided by applicant): The aim of this proposal is to develop a bioinformatics pipeline, or Integrated Bioinformatics Analysis Suite (IBAS), specific for ultra-deep, targeted amplicon sequencing on the new Ion Torrent Personal Genome Machine(PGM). This will improve the accuracy of… More

Development of clinical triage assay for sepsis management in the Emergency Room

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jennifer Skeen – 512-681-5200
Award Amount: $314,420.00
Abstract:
DESCRIPTION (provided by applicant): The overall project objective is to further develop and clinically validate an assay, SeptiCyte(R)Triage, to improve screening and early diagnosis of conditions associated with inflammation and sepsis in Emergency Room(ER). The test will deliver clinically… More

Enabling use of blood spot cards for accurate high throughput Fragile X screening

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Gary J. Latham – 512-651-0200
Award Amount: $2,153,865.00
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this project is to develop accurate, rapid, high throughput and cost-effective screening for fragile X syndrome (FXS) and related disorders. FXS is the most common known genetic cause of autism andinherited intellectual disability, and… More

SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ph.d Brown – 512-681-5246
Award Amount: $241,044.00
Abstract:
Asuragen is developing a sensitive, accurate, and reliable test (BCR-ABL1 RT-qPCR Test), for quantification of BCR-ABL1 fusion transcripts to monitor residual disease in patients with chronic myeloid leukemia (CML). Molecular testing for the presence and relative amount of the BCR-ABL1 translocation… More